Is JVInvest stock valuation data free and transparent?

Yes, all valuation data on JVInvest is 100% free and transparent. We provide verifiable P/E ratios for the Top 100 global stocks, S&P 500, Nasdaq 100, and major indices worldwide. All data sources are disclosed so you can verify every calculation yourself.

What valuation metrics are available on JVInvest?

JVInvest provides transparent P/E ratios for Top 100 global stocks (MSCI World), S&P 500, Nasdaq 100, DAX, FTSE 100, Nikkei 225 and more. All valuation metrics are verifiable with disclosed quarterly EPS data and market prices.

Do I need to create an account to access the data?

No account or signup is required. All S&P 500 fundamental data is freely accessible without registration.

How can I verify the P/E ratio calculations?

All our valuation data is 100% transparent. We disclose all data sources, quarterly EPS figures, and market prices used in calculations. You can verify every P/E ratio yourself using our transparent methodology.

What is a Sankey chart for stocks?

A Sankey chart visualizes the flow of money through a company's financial statements - showing how revenue flows to costs, operating income, net income, and cash flows. JVInvest offers free Sankey charts for all S&P 500 companies.

Which stock indices have free valuation data?

JVInvest provides free, verifiable valuation data for major global indices: S&P 500, Nasdaq 100, DAX 40, FTSE 100, CAC 40, Nikkei 225, and the Top 100 MSCI World stocks. All index P/E ratios are calculated transparently.

What is the current S&P 500 P/E ratio?

JVInvest calculates and displays the current S&P 500 index P/E ratio based on the aggregate earnings of all constituent companies. Visit the Valuation page for the latest P/E ratio data.

Daily Market Report – January 27, 2026

Name: Transparent Stock Valuation Data (English & German)
Creator: JVInvest
License: https://creativecommons.org/licenses/by/4.0/

Financial Market Today (Tue., 01/27/2026; US Market Close)

US stocks held up well overall – the S&P 500 marked a new record high, although the healthcare sector significantly dampened the mood. The losses of health insurers primarily impacted the Dow through UnitedHealth UNH.

US Dollar: The dollar fell sharply; the broad dollar index dropped to its lowest level in nearly four years (TVC:DXY). Political uncertainty and statements from Trump led to a significant decline in the US dollar. The yen traded stronger, supported by ongoing speculation about measures to support the yen ("rate checks"/intervention risk).

UnitedHealth UNH plummeted by −19.6%. The US government/CMS projected only +0.09% higher reimbursements for 2027 – far below what the market had anticipated. This affected the entire sector. However, the key reason for the sharp decline of UnitedHealth was the disappointing revenue/earnings outlook and comments on cost developments (including Medicaid/medical costs). UnitedHealth expects fewer insured individuals and a "contraction" of Optum Health. Following the company's outlook, analysts forecast a revenue decline for 2026. The stock plunge dragged down Humana, CVS & Co. as well.

Täglicher Marktbericht – 27. Januar 2026

Finanzmarkt heute (Di., 27.01.2026; US-Handelsschluss)

US-Aktien hielten sich insgesamt gut – der S&P 500 markierte ein neues Rekordhoch, obwohl der Gesundheitssektor die Stimmung deutlich bremste. Die Verluste der Krankenversicherer wirkten vor allem über UnitedHealth auf den Dow.

US-Dollar: Der Dollar rutschte deutlich ab; der breite Dollar-Index fiel auf den tiefsten Stand seit fast vier Jahren (TVC:DXY). Politische Unsicherheit sowie Aussagen von Trump führten dazu, dass der US-Dollar deutlich nachgab. Der Yen notierte fester, gestützt durch anhaltende Spekulationen über Schritte zur Yen-Stützung („Rate-Checks“/Interventionsrisiko).

UnitedHealth NYSE:UNH brach um −19,6% ein. Die US-Regierung/CMS stellte für 2027 nur +0,09% höhere Vergütungen in Aussicht – weit unter dem, womit der Markt gerechnet hatte. Das traf den ganzen Sektor. Aber der entscheidende Grund für den starken Rückgang von UnitedHealth war der enttäuschende Umsatz-/Ertragsausblick und Aussagen zur Kostenentwicklung (u. a. Medicaid/Medizinkosten). United Health rechnet mit weniger Versicherten sowie einer Verkleinerung“ von Optum Health. Nach dem Ausblick des Unternehmens rechnen Analysten für 2026 mit einem Umsatzrückgang. Der Kurssturz zog Humana, CVS & Co. mit nach unten.